A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma

Xie, Yandong; Lu, Xueying; Wang, Zhen; Liu, Mingxi; Liu, Liang; Wang, Ran; Yang, Kun; Xiao, Hong; Li, Jianyong; Tang, Xianglong; Liu, Hongyi

doi:10.1039/d2bm01145j

Cited by 8 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development and advances in nanotechnology, nanomaterials are emerging as ideal non-viral vectors capable of overcoming multiple biological barriers of nucleic acid delivery to GBM. For example, Xie et al 69 designed an attractive liposome-based hypoxia-radiosensitive nanoparticle nanoplatform denoted RDPP(Met)/TMZ/siMGMT for co-delivery of TMZ and siMGMT. Xie et al 69 encapsulated TMZ into RDPP by hydrophobic interaction and attached siMGMT to the surface of RDPP via an electrostatic interaction.…”

Section: Nanomedicine-based Combination Therapies To Overcome Drug Re...mentioning

confidence: 99%

“…For example, Xie et al 69 designed an attractive liposome-based hypoxia-radiosensitive nanoparticle nanoplatform denoted RDPP(Met)/TMZ/siMGMT for co-delivery of TMZ and siMGMT. Xie et al 69 encapsulated TMZ into RDPP by hydrophobic interaction and attached siMGMT to the surface of RDPP via an electrostatic interaction. Furthermore, surface modification of RGD facilitated RDPP to transport TMZ and siMGMT across the BBB and targeted GBM.…”

Section: Nanomedicine-based Combination Therapies To Overcome Drug Re...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Wang

Xiao

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common malignant brain tumor. Although current treatment strategies, including surgery, chemotherapy, and radiotherapy, have achieved clinical effects and prolonged the survival of patients, the gradual development of resistance against current therapies has led to a high recurrence rate and treatment failure. Mechanisms underlying the development of resistance involve multiple factors, including drug efflux, DNA damage repair, glioma stem cells, and a hypoxic tumor environment, which are usually correlative and promote each other. As many potential therapeutic targets have been discovered, combination therapy that regulates multiple resistance-related molecule pathways is considered an attractive strategy. In recent years, nanomedicine has revolutionized cancer therapies with optimized accumulation, penetration, internalization, and controlled release. Blood-brain barrier (BBB) penetration efficiency is also significantly improved through modifying ligands on nanomedicine and interacting with the receptors or transporters on the BBB. Moreover, different drugs for combination therapy usually process different pharmacokinetics and biodistribution, which can be further optimized with drug delivery systems to maximize the therapeutic efficiency of combination therapies. Herein the current achievements in nanomedicine-based combination therapy for GBM are discussed. This review aimed to provide a broader understanding of resistance mechanisms and nanomedicine-based combination therapies for future research on GBM treatment.

show abstract

Section: Nanomedicine-based Combination Therapies To Overcome Drug Re...mentioning

confidence: 99%

Section: Nanomedicine-based Combination Therapies To Overcome Drug Re...mentioning

confidence: 99%

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Wang

Xiao

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…[ 8,9 ] Due to the demand, some technologies such as liposomes, siRNA nanoplatform, and CRISPR‐Cas 9 have been tried to be applied to open the BBB so as to increase the dosage of drugs reaching the brain lesion. [ 3,10–12 ] The first use of focused ultrasound and drug delivery in the central nervous system dates to the early 1940s. [ 13 ] At present, focused ultrasound technology is relatively mature, and combined with non‐microbubbles, it shows a high degree of spatial and temporal specificity.…”

Section: Introductionmentioning

confidence: 99%

Saponin‐Encapsulated Microbubbles Protect Dopaminergic Neurons from MPTP‐Induced Oxidative Stress Injury

Zhang

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Parkinson's disease (PD) is starting at younger ages. In order to reduce the risk of PD in young people, Rb3 is selected as an active ingredient and assembled into Rb3 nanoparticles (Rb3NPs)encapsulated microbubbles (MBs), shorted for Rb3NPs@MBs. This study uses focused ultrasound‐mediated Rb3NPs@MBs to cross the blood–brain barrier and reach the brain lesions to be intervened in in order to explore the prevention of 1‐methyl‐4‐phenyl‐4‐piperidinpropionate ester (MPTP)‐induced PD by Rb3NPs@MBs and its related mechanisms. In the present study, Rb3NPs@MBs prevent MPTP‐induced tyrosine hydroxylase (TH)‐positive cell decreases, decrease TH expression, increase Park2 expression, and decrease expression of α‐synaptonucleoprotein in the pars compactus nigra (SNc). It is found, in vitro study, that Rb3NPs treatment significantly reverses MPTP‐induced apoptosis and death of PC12/SY5Y cells, which is commonly used mouse/ human neural cell lines. It is also found that Rb3NPs@MBs can prevent the production of reactive oxygen species (ROS) in SNc. Finally, it is found that DJ‐1 expression decreases after Rb3NPs@MBs are introduced. Results suggest that the neuroprotective activity of Rb3NPs@MBs may be achieved by increasing the expression of DJ‐1 and decreasing the production of ROS. Taken together, these data reveal that Rb3NPs@MBs play an important role in preventing memory deficiency in PD.

show abstract

Enhancing X‐Ray Sensitization with Multifunctional Nanoparticles

Liu,

Wu,

Chen

et al. 2024

Small

View full text Add to dashboard Cite

In the progression of X‐ray‐based radiotherapy for the treatment of cancer, the incorporation of nanoparticles (NPs) has a transformative impact. This study investigates the potential of NPs, particularly those comprised of high atomic number elements, as radiosensitizers. This aims to optimize localized radiation doses within tumors, thereby maximizing therapeutic efficacy while preserving surrounding tissues. The multifaceted applications of NPs in radiotherapy encompass collaborative interactions with chemotherapeutic, immunotherapeutic, and targeted pharmaceuticals, along with contributions to photodynamic/photothermal therapy, imaging enhancement, and the integration of artificial intelligence technology. Despite promising preclinical outcomes, the paper acknowledges challenges in the clinical translation of these findings. The conclusion maintains an optimistic stance, emphasizing ongoing trials and technological advancements that bolster personalized treatment approaches. The paper advocates for continuous research and clinical validation, envisioning the integration of NPs as a revolutionary paradigm in cancer therapy, ultimately enhancing patient outcomes.

show abstract

A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma

Abstract: Glioblastoma (GBM), as the most aggressive adult brain tumor, seriously threatened people’s life with a low survival time. Standard postoperative treatment, chemotherapy combined with radiotherapy (RT), was the major therapeutic...

Cited by 8 publications

References 31 publications

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

Saponin‐Encapsulated Microbubbles Protect Dopaminergic Neurons from MPTP‐Induced Oxidative Stress Injury

Enhancing X‐Ray Sensitization with Multifunctional Nanoparticles

Contact Info

Product

Resources

About